

1 **Analysis of antimicrobial activity of aqua alcoholic extract of *Boerhaviadiffusa* against**  
2 **oral pathogens -An Invitro study**

3

4

5 **ABSTRACT**

6 **INTRODUCTION**

7 *Boerhaviadiffusa*(*Mukkirattai*) of the *Nyctaginaceae* family is a widely used folk medicinal  
8 plant that grows as a common weed with its leaves, seeds and roots are useful parts with  
9 pharmacological activities with a cure for twenty-three ailments. Phytochemical constituents  
10 of *B.diffusa* showing antimicrobial activity includes phenols, flavonoids, tannins, saponins,  
11 alkaloids, glycosides.

**Comment [bs1]:** How to write this plant, it is separate or connected like this?

12 **AIM**

13 The present study aimed to evaluate the qualitative analysis of the antimicrobial activity of  
14 aqua alcoholic extracts of *Boerhaviadiffusa* L. (Family: *Nyctaginaceae*) leaves.

15 **MATERIALS AND METHODS**

16 *Boerhaviadiffusa* (*Mukkirattai*) was freshly procured as a powdered form and the  
17 antimicrobial activity of different solvent extracts of *B. diffusa* were tested against the Gram-  
18 positive bacteria and fungal strains by observing the zone of inhibition. The Gram-positive  
19 bacteria used in the test were *Staphylococcus aureus*, *Enterococcus faecalis*, *Streptococcus*  
20 *mutans* and fungal strains *Candida albicans* were used. The obtained data were analysed  
21 statistically by Non parametric Spearman correlation analysis.

22 **RESULTS**

23 Antimicrobial activity was observed in the aqueous-alcoholic extracts against Gram-positive  
24 bacilli , cocci and fungal strains. The aqua alcoholic extract of *B. diffusa* showed positive  
25 correlation with p value less than 0.05 with antimicrobial effect against fungal strains(e.g. *C.*  
26 *albicans*, the zone of inhibition diameter of 26mm) and against Gram-positive bacteria(e.g. *S.*  
27 *aureus*, the zone of inhibition diameter of 20 mm) and then Gram-positive cocci (e.g.  
28 *S.Mutans*, the zone of inhibition diameter of 18 mm) when compared to *E.faecalis*.

29

30 **CONCLUSION**

31 The Aqua Alcoholic extract of *Boerhaviadiffusa* has a very strong Antimicrobial activity  
32 against *Candida Albicans* and *Staphylococcus Aureus* while it showed minimal antimicrobial  
33 activity against *Enterococcus faecalis* and *Streptococcus mutans* and showed excellent  
34 potential as an antimicrobial agent and also as a biofriendly, inexpensive.

35 **Keywords***Boerhaviadiffusa*, Antimicrobial, Aqua alcoholic extract, Green synthesis, Zone of  
36 inhibition, *Nyctaginaceae*

37 **Running title:**Antimicrobial Activity of Aqua-alcoholic Extract of *BoerhaaviaDiffusa*

38  
39

40

## 41 INTRODUCTION

42 The *Boerhavia* genus distributed in the tropics of Asia, Africa, and Australia has around forty  
43 species. *Boerhaviadiffusa* of the *Nyctaginaceae* family is a widely used folk medicinal plant  
44 <sup>(1)</sup>.*B.diffusa*grows as a common weed with its leaves, seeds and roots are the useful parts with  
45 pharmacological activities with a cure for twenty-three ailments includes cardioprotective  
46 effect, treatment of prostatic hyperplasia, anti-inflammatory action, anxiolytic activity,  
47 protective effect on gastrointestinal problems, anticancer activity, antimicrobial activity,  
48 protection against harmful radiations, hepatoprotective activity, anti-arthritic activity and  
49 antidiabetic activity.<sup>(2,3)</sup> Other Indian names include varshabhu, Tambadivasu, Snathikari. It  
50 also helps in resolving abdominal pain, jaundice, diabetes, elephantiasis, ulcers, etc.,  
51 <sup>(4)</sup>Phenols, flavonoids, tannins, saponins, alkaloids, glycosides are the basic aqua-alcoholic  
52 phytochemical constituents of *B.diffusa* showing antimicrobial activity and in previous  
53 studies showed the presence of flavonoids, alkaloids, steroids, triterpenoids, lipids, lignins,  
54 carbohydrates, proteins and glycoproteins in *B.diffusa*extracts<sup>(5-7)</sup>. Alcoholic and alkaline  
55 phytochemical flavonoids extract of *B.diffusa*is more compared to phenols and alkaloids<sup>(8)</sup>

56 The seeds of *Boerhaviadiffusa*have anti-bacterial, anti-fungal and anti-pathogenic activity  
57 against *E.faecalis*, *S.aureus*, *S.mutans*, *C.albicans*.<sup>(9,10)</sup> Antibiotics result in multidrug  
58 resistance in treating infectious disease also associated with anaphylactic reactions.<sup>(11)</sup> This  
59 forced the physicians to create new antimicrobial substances from medicinal plants with  
60 fewer hypersensitivity reactions. *B. diffusa* is also used in Ayurvedic medicine in India and as  
61 an Unani medicine in Arab countries for the treatment of various factors like inflammation,  
62 jaundice, enlargement of spleen, congestive heart failure, diabetes, stress, dyspepsia,  
63 abdominal pain. <sup>(12-15)</sup> It has also been reported that *Boerhaaviadiffusa*is useful in the  
64 treatment of corneal ulcers, nephritic syndrome, elephantiasis, night blindness.<sup>(16-18)</sup>

65 Several screening studies have been carried out in different parts of the world. Plant-based  
66 antimicrobials are the source of medicines with multiple therapeutic potentials.<sup>(19)</sup> Both stem  
67 and leaf extract was tested against seven fungi species and six bacterial species, two types of  
68 yeast which showed antimicrobial activity in a dose-dependent manner (300-1800µg) and our  
69 team has extensive knowledge and research experience that has translate into high quality  
70 publications <sup>(20),(21-34),(35-39)</sup> In this present investigation, we have analysed the antimicrobial  
71 activity of aqua alcoholic extract of *Boerhaaviadiffusa*.

## 72 MATERIALS AND METHODS

### 73 Preparation of plant extract

74 *Boerhaviadiffusa* (Mukkirattai) was freshly procured from Nature and Nurture health care Pvt  
75 limited, New delhi as a powdered form which is the main advantage in our study.  
76 *Boerhaviadiffusa* is a commonly available leaf in southern India and is well known for its  
77 health benefits. It is the best green medicine for diabetes. Aqueous-alcoholic extract was  
78 prepared in the nanotechnology lab of Saveetha Dental College and Hospital. This original

Comment [bs2]: ( Superscript

79 study protocol was reviewed and approved by the research ethical committee of Saveetha  
80 Dental College and Hospitals, Chennai, Tamilnadu, India.  
81

82 For preparing an aqueous-alcoholic extract, 50 ml of ethanol is measured using a measuring  
83 cylinder. 5g of powdered *B. diffusawas* added to the 50 ml of ethanol and mixed well. Now  
84 the extract is transferred to the glass beaker and 50 ml of distilled water is added to the  
85 alcoholic extract. The beaker with aqueous-alcoholic extract of *Boerhaviadiffusa* is covered  
86 with aluminum foil paper and then kept in an orbital shaker for general mixing of the extract  
87 at 79.20 rpm. After 24 hours the extract was transferred to the measuring cylinder and the  
88 extract was boiled at 10% for 20 minutes and the extract was cooled at room temperature.

### 89 **Antimicrobial activity**

#### 90 **Antibacterial Activity**

91 Antibacterial activity of respective nanoparticles against the strain *staphylococcus aureus*,  
92 *Enterococcus faecalis*, and *staphylococcus mutans*. MHA agar was utilized for this activity to  
93 determine the zone of inhibition. Muller Hinton agar was prepared and sterilized for 45  
94 minutes at 120lbs. Media poured into the sterilized plates and let them stabilize for  
95 solidification. The wells were cut using the well cutter and the test organisms were swabbed.  
96 The plant extract at 25µL, 50µL, 100µL, 150µL concentrations were loaded and plates were  
97 incubated for 24 hours at 37 ° C. After the incubation time the zone of inhibition was  
98 measured. Manual labelling of the organisms should be given to avoid manual error.

99

#### 100 **Antifungal activity**


101 *Candida albicans* are used as test pathogens by agar well diffusion assay. Sabouraud's  
102 dextrose Agar is used to prepare the medium. The prepared and sterilized medium was  
103 swabbed with test organisms and nanoparticles with different concentrations were added to  
104 the wells. The plates were incubated at 28° C for 48-72hours. After the incubation time, the  
105 zone of inhibition was measured and tabulated. The data obtained were tabulated and  
106 analysed by non parametric spearman correlation analysis using SPSS version 23.

### 107 **RESULTS AND DISCUSSION**


108 The anti-microbial activity of aqua-alcoholic extract of *Boerhaaviadiffusa* against  
109 *Streptococcus mutans*, *Staphylococcus aureus*, *Enterococcus faecalis*, and *Candida albicans*  
110 summarized in Figure 3. The result revealed that *Boerhaaviadiffusashowed* antimicrobial  
111 activity of different magnitudes. The zone of inhibition at different concentrations (25µL,  
112 50µL, 100µL, 150µL) was done showing a reduction of the diameter of colonies around  
113 26mm for *C.albicans*, 20mm for *S.aureus*, 18mm for *S.mutans* and 17mm for *S.faecalis*.  
114 Microorganisms are sensitive to different components of extracts of *Boerhaaviadiffusa*.  
115 Spearman correlation analysis showed positive correlation ( $r=1$ ) of decrease in zone of  
116 inhibition (mm) with increase in concentration and significant p value of less than 0.023. The  
117 sensitivity of bacterial and fungal species is observed in the following decreasing order  
118 *C.albicans*>*S.aureus*>*S.mutans*>*E.faecalis*.

Comment [bs3]: words are connected

Comment [bs4]: words are connected




119  
 120 Figure 1 Schematic representation of Preparation of *Boerhaviadiffusa* extract. A-powdered  
 121 extract of *Boerhaaviadiffusa*. B-Aqua Alcoholic extract of *Boerhaaviadiffusa*.



122  
 123  
 124 **Figure 2** Anti-microbial activity of *B.diffusa* extract on A - *Streptococcus mutans*, B -  
 125 *Staphylococcus aureus*, C - *Enterococcus faecalis*, andD -*C.albicans*

126  
 127




128

129 **Figure 3:** Bar graph depicts the concentration of antimicrobial activity (x axis) of Aqua -  
 130 alcoholic extract of *Boerhaaviadiffusa* and the zone of inhibition (y axis). Positive correlation  
 131 ( $r=1$ ) with  $p$  value  $<0.05$  is observed with increasing concentration of Aqua -alcoholic extract  
 132 of *Boerhaaviadiffusa*. Blue colour denotes staphylococcus faecalis, green represents  
 133 staphylococcus aureus, grey represents streptococcus mutans, purple represents candida  
 134 albicans. From this it is inferred that albicans showed maximum zone of inhibition with the  
 135 least seen in faecalis.

136

Comment [bs5]: words are connected

Comment [bs6]: words are connected



137

138 **Figure 4** Line Graph depicts the zone of inhibition of *Candida Albicans* was higher with  
 139 increase in concentration.

140 TABLE-1 - Depicts the zone of inhibition for *Streptococcus mutans*, *Staphylococcus*  
 141 *aureus*, *Enterococcus faecalis*, *Candida albicans* at increasing concentrations.

Concentration	25 μL	50 μL	100μL	150 μL
<i>E.faecalis</i>	9mm	11mm	15mm	17mm
<i>S. aureus</i>	9mm	12mm	18mm	20mm
<i>S. mutans</i>	10mm	13mm	15mm	18mm
<i>C.albicans</i>	14mm	18mm	25mm	26mm

142

143 In the present study, the zone of inhibition for *Enterococcus faecalis* at 25μL was 9mm, at  
 144 50μL it was 11mm and for 100μL it was 15mm and for 150μL it is 17mm. The zone of  
 145 inhibition for *staphylococcus aureus* at 25μL is 9mm and at 50μL it is 12mm and at 100μL it  
 146 is 18mm and at 150μL it is 20mm. The zone of inhibition for *streptococcus mutans* at 25μL  
 147 is 10mm and at 50μL it is 13mm and for 100μL it is 15mm and at 150μL it is 18mm. The  
 148 zone of inhibition for *Candida albicans* at 25μL is 14mm and at 50μL it is 18mm and at  
 149 100μL it is 25mm and at 150μL it is 26mm.

150 Rotenoids are prototype compound named rotenone and isoflavonoids derivative a  
151 mitochondrial inhibitor causes ion inhibition electron transport chain in mitochondria at  
152 complex I, “toxophore” prenyl-derived ring of rotenoid structure and dimethoxy substitute to  
153 rotenone. Rotenoids isolated from *Boerhaaviadiffusa* are noncytotoxic due to the lack of  
154 isoprenoid residue.<sup>(40)</sup>

Comment [bs7]:  
words are connected

155 *Staphylococcus and Streptococcus*, Gram-positive bacteria invades skin, tissues, and  
156 bloodstreams. Coagulases, proteins activate the hemostatic factor prothrombin of the host,  
157 Surface of bacteria display agglutinins, proteins and fibrin are the virulence factors of *S.*  
158 *aureus* infections leading to the destruction of immune cells, resulting in purulent exudate.<sup>(41)</sup>  
159 *S. aureus* has superantigen (SSL5&SSL10), prevents rolling and adherence of neutrophil  
160 along endothelium. *S. aureus* diminishes opsonization by targeting complement activation  
161 systems.<sup>(42)</sup>

162 *Candida albicans* adhesion(adhesins) and invasion into host cells with the secretion of  
163 hydrolases, yeast hyphae transition, thigmotropism, phenotypic switching, altered pH biofilm  
164 formation (Hwp1 and Als3) Secreted aspartic proteases (Saps) lead to endocytosis of *C.*  
165 *Albicans*. The utilization of lipases and amino acids results in hyphae formation. Hog1-,  
166 Mkc1-, Cek1-MAP kinase pathway responsible for maintaining the integrity of candida to the  
167 host surface.<sup>(43)</sup> *Candida albicans* adhere to the host surface with adhesin expression yeast-  
168 hyphae transition, growth by thigmotropism, Invasins mediate endocytosis of fungus into the  
169 host cell breaking down the barriers. Heat shock proteins, amino acids, lipases, ammonia  
170 excretion, and different trace compounds like zinc, carbon, manganese are responsible for  
171 hyphae formation.

172 Extract of *Boerhaaviadiffusa* induced systemic resistance active component BDP-30 a  
173 glycoprotein, pI greater than 9.0 with amino acid sequence KLYDIPPLR is responsible for  
174 antimicrobial activity by inhibiting bacterial transduction between the host and the recipient  
175 cells also inhibits candida albicans biofilm formation by preventing dimorphism and  
176 switching of candidal hyphae formation<sup>(44)</sup>. The limitations of the study are constrained with  
177 four microorganisms at different concentrations. In future similar study in large scale  
178 productions for targeted drug delivery to treat and prevent a wide array of oral microbial  
179 infections.

180

## 181 CONCLUSION

182 The Aqua Alcoholic extract of *Boerhaviadiffusa* has a very strong Antimicrobial activity  
183 against *Candida Albicans* and *Staphylococcus Aureus* while it showed minimal antimicrobial  
184 activity against *Enterococcus faecalis* and *Streptococcus mutans* and showed excellent  
185 potential as an antimicrobial agent and also as a biofriendly, inexpensive.

186

### • **COMPETING INTERESTS DISCLAIMER:**

187

188

- Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

189

190

191

192

193

194

•

- 195 •
- 196 •
- 197 •

198 **REFERENCE**

199. Nugraha AS. Bioactive compounds from *Boerhavia erecta* L.: an African medicinal plant. 2009; Available from: <http://ro.uow.edu.au/cgi/viewcontent.cgi?article=4676&context=theses>
202. Patel SS, Raghuvanshi R, Masood M, Acharya A, Jain SK. Medicinal plants with acetylcholinesterase inhibitory activity. *Rev Neurosci*. 2018 Jul 26;29(5):491–529.
203. Preethikaa S, Brundha MP. Awareness of diabetes mellitus among general population. *Research Journal of Pharmacy and Technology*. 2018;11(5):1825–9.
204. Subramoniam A. *Anti-Diabetes Mellitus Plants: Active Principles, Mechanisms of Action and Sustainable Utilization*. CRC Press; 2016. 390 p.
205. Agarwal RR, Dutt SS. Chemical examination of punarnava or *Boerhaaviadiffusa* Linn. II. Isolation of an alkaloid punarnavine. *Chem Abst*. 1936;30:3585.
206. Basu NK, Lal SB. Investigations on Indian medicinal plants. *Q J Pharm Pharmacol*. 1947 Jan;20(1):38; passim.
211. Surange SR, Pendse GS. Pharmacognostic study of roots of *Boerhaaviadiffusa* Willd. (punarnava). *J Res Indian Med*. 1972;7(1).
218. Jayachitra J, Janani B, Bharathi V, Manikandan R. Phytochemical analysis and mineral composition of Methanolic extract of *Boerhavia diffusa* L [Internet]. Vol. 13, *Research Journal of Pharmacy and Technology*. 2020. p. 4856. Available from: <http://dx.doi.org/10.5958/0974-360x.2020.00854.9>
219. Prasad R, Jha AK, Prasad K. *Exploring the Realms of Nature for Nanosynthesis*. Springer; 2018. 414 p.
219. Brundha MP, Pathmashri VP, Sundari S. Quantitative Changes of Red Blood cells in Cancer Patients under Palliative Radiotherapy-A Retrospective Study. *Research Journal of Pharmacy and Technology*. 2019;12(2):687–92.
221. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World journal of gastrointestinal* [Internet]. 2017; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5547374/>
222. Kīrtikara KR, Basu BD. *Indian medicinal plants* / [Internet]. 1918. Available from: <http://dx.doi.org/10.5962/bhl.title.137025>
223. Dagogo-Jack S. *Diabetes Mellitus in Developing Countries and Underserved Communities*. Springer; 2016. 294 p.
224. Chopra RN, Nayar SL, Chopra IC, Others. *Glossary of Indian medicinal plants*. Vol. 1. Council of Scientific & Industrial Research New Delhi; 1956.

2315. Mishra JP, Others. Studies on the effect of indigenous drug Boerhaaviadiffusa Rom. on  
232 kidney regeneration. *Indian J Pharm.* 1980;12(59):1487–98.
2336. Singh RH, Udupa KN. Studies on the Indian indigenous drug Punarnava (Boerhaaviadiffusa  
234 L.) Part I, Identification and pharmacological studies. *J Res Indian Med.* 1972;7:1–12.
2357. Bharali R, Azad MRH, Tabassum J. Chemopreventive action of Boerhaaviadiffusa on  
236 DMBA-induced skin carcinogenesis in mice. *Indian J PhysiolPharmacol.* 2003  
237 Oct;47(4):459–64.
2388. Timothy CN, Samyuktha PS, Brundha MP. Dental pulp Stem Cells in Regenerative  
239 Medicine--A Literature Review. *Research Journal of Pharmacy and Technology.*  
240 2019;12(8):4052–6.
2419. van Vuuren S, Viljoen A. Plant-based antimicrobial studies--methods and approaches to  
242 study the interaction between natural products. *Planta Med.* 2011 Jul;77(11):1168–82.
2430. Anita R, Paramasivam A, Priyadharsini JV, Chitra S. The m6A readers YTHDF1 and  
244 YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer  
245 patients. *Am J Cancer Res.* 2020 Aug 1;10(8):2546–54.
2481. Jayaseelan VP, Paramasivam A. Emerging role of NET inhibitors in cardiovascular diseases.  
247 *Hypertens Res.* 2020 Dec;43(12):1459–61.
2482. Sivakumar S, SmilineGirija AS, VijayashreePriyadharsini J. Evaluation of the inhibitory  
249 effect of caffeic acid and gallic acid on tetR and tetM efflux pumps mediating tetracycline  
250 resistance in *Streptococcus* sp., using computational approach. *Journal of King Saud  
251 University - Science.* 2020 Jan 1;32(1):904–9.
2523. SmilineGirija AS. Delineating the Immuno-Dominant Antigenic Vaccine Peptides Against  
253 gacS-Sensor Kinase in *Acinetobacter baumannii*: An in silico Investigational Approach.  
254 *Front Microbiol.* 2020 Sep 8;11:2078.
2584. IswaryaJaisankar A, SmilineGirija AS, Gunasekaran S, VijayashreePriyadharsini J.  
256 Molecular characterisation of csgA gene among ESBL strains of *A. baumannii* and targeting  
257 with essential oil compounds from *Azadirachta indica*. *Journal of King Saud University -  
258 Science.* 2020 Dec 1;32(8):3380–7.
2595. Girija ASS. Fox3+ CD25+ CD4+ T-regulatory cells may transform the nCoV's final destiny  
260 to CNS! *J Med Virol* [Internet]. 2020 Sep 3; Available from:  
261 <http://dx.doi.org/10.1002/jmv.26482>
2626. Jayaseelan VP, Ramesh A, Arumugam P. Breast cancer and DDT: putative interactions,  
263 associated gene alterations, and molecular pathways. *Environ Sci Pollut Res Int.* 2021  
264 Jun;28(21):27162–73.
2637. Arumugam P, George R, Jayaseelan VP. Aberrations of m6A regulators are associated with  
266 tumorigenesis and metastasis in head and neck squamous cell carcinoma. *Arch Oral Biol.*  
267 2021 Feb;122:105030.
2688. Kumar SP, Girija ASS, Priyadharsini JV. Targeting NM23-H1-mediated inhibition of tumour  
269 metastasis in viral hepatitis with bioactive compounds from *Ganoderma lucidum*: A

- 270 computational study. pharmaceutical-sciences [Internet]. 2020;82(2). Available from:  
271 <https://www.ijpsonline.com/articles/targeting-nm23h1mediated-inhibition-of-tumour->  
272 [metastasis-in-viral-hepatitis-with-bioactive-compounds-from-ganoderma-lucidum-a-comp-](https://www.ijpsonline.com/articles/targeting-nm23h1mediated-inhibition-of-tumour-metastasis-in-viral-hepatitis-with-bioactive-compounds-from-ganoderma-lucidum-a-comp-3883.html)  
273 [3883.html](https://www.ijpsonline.com/articles/targeting-nm23h1mediated-inhibition-of-tumour-metastasis-in-viral-hepatitis-with-bioactive-compounds-from-ganoderma-lucidum-a-comp-3883.html)
2729. Girija SA, Priyadharsini JV, Paramasivam A. Prevalence of carbapenem-hydrolyzing OXA-  
275 type  $\beta$ -lactamases among *Acinetobacter baumannii* in patients with severe urinary tract  
276 infection. *Acta Microbiol Immunol Hung*. 2019 Dec 9;67(1):49–55.
2730. Priyadharsini JV, Paramasivam A. RNA editors: key regulators of viral response in cancer  
278 patients. *Epigenomics*. 2021 Feb;13(3):165–7.
2791. Mathivadani V, Smiline AS, Priyadharsini JV. Targeting Epstein-Barr virus nuclear antigen 1  
280 (EBNA-1) with Murrayakoengii bio-compounds: An in-silico approach. *Acta Virol*.  
281 2020;64(1):93–9.
2822. Girija As S, Priyadharsini J V, A P. Prevalence of Acb and non-Acb complex in elderly  
283 population with urinary tract infection (UTI). *Acta Clin Belg*. 2021 Apr;76(2):106–12.
2843. Anchana SR, Girija SAS, Gunasekaran S, Priyadharsini VJ. Detection of *csgA* gene in  
285 carbapenem-resistant *Acinetobacter baumannii* strains and targeting with *Ocimum sanctum*  
286 biocompounds. *Iran J Basic Med Sci*. 2021 May;24(5):690–8.
2834. Girija ASS, Shoba G, Priyadharsini JV. Accessing the T-Cell and B-Cell Immuno-Dominant  
288 Peptides from *A.baumannii* Biofilm Associated Protein (bap) as Vaccine Candidates: A  
289 Computational Approach. *Int J Pept Res Ther*. 2021 Mar 1;27(1):37–45.
2905. Arvind P TR, Jain RK. Skeletally anchored forsus fatigue resistant device for correction of  
291 Class II malocclusions-A systematic review and meta-analysis. *OrthodCraniofac Res*. 2021  
292 Feb;24(1):52–61.
2936. Venugopal A, Vaid N, Bowman SJ. Outstanding, yet redundant? After all, you may be  
294 another *Cholutedca* Bridge! *Semin Orthod*. 2021 Mar 1;27(1):53–6.
2937. Ramadurai N, Gurunathan D, Samuel AV, Subramanian E, Rodrigues SJL. Effectiveness of  
296 2% Articaine as an anesthetic agent in children: randomized controlled trial. *Clin Oral*  
297 *Investig*. 2019 Sep;23(9):3543–50.
2988. Varghese SS, Ramesh A, Veeraiyan DN. Blended Module-Based Teaching in Biostatistics  
299 and Research Methodology: A Retrospective Study with Postgraduate Dental Students. *J*  
300 *Dent Educ*. 2019 Apr;83(4):445–50.
3039. Mathew MG, Samuel SR, Soni AJ, Roopa KB. Evaluation of adhesion of *Streptococcus*  
302 *mutans*, plaque accumulation on zirconia and stainless steel crowns, and surrounding gingival  
303 inflammation in primary molars: randomized controlled trial [Internet]. Vol. 24, *Clinical Oral*  
304 *Investigations*. 2020. p. 3275–80. Available from: [http://dx.doi.org/10.1007/s00784-020-](http://dx.doi.org/10.1007/s00784-020-03204-9)  
305 [03204-9](http://dx.doi.org/10.1007/s00784-020-03204-9)
3040. Crombie L, Josephs JL, Cayley J, Larkin J, Weston JB. The rotenoid core structure:  
307 Modifications to define the requirements of the toxophore. *Bioorg Med Chem Lett*. 1992 Jan  
308 1;2(1):13–6.

3091. Thomer L, Schneewind O, Missiakas D. Pathogenesis of *Staphylococcus aureus* Bloodstream  
310 Infections. *Annu Rev Pathol: Mech Dis*. 2016 May 23;11(1):343–64.
3142. Stapels DAC, Ramyar KX, Ricklin D, Milder FJJ, Bischoff M, Herrmann M, et al.  
312 Extracellular adherence protein (Eap) of *Staphylococcus aureus* evades innate immunity by  
313 inhibiting complement activation and neutrophil elastase [Internet]. Vol. 217,  
314 Immunobiology. 2012. p. 1170. Available from:  
315 <http://dx.doi.org/10.1016/j.imbio.2012.08.118>
3143. Prasad R. *Candida Albicans: Cellular and Molecular Biology*. Springer Science & Business  
317 Media; 2012. 267 p.
3144. Srivastava S, Verma HN, Srivastava A, Prasad V. BDP-30, a systemic resistance inducer  
319 from *Boerhaaviadiffusa* L., suppresses TMV infection, and displays homology with  
320 ribosome-inactivating proteins. *J Biosci*. 2015 Mar;40(1):125–35.

321

UNDER PEER REVIEW